Madrigal Pharmaceuticals, Inc. is an American biotechnology company focused on developing new therapeutic drugs for liver and cardiometabolic diseases. The company specializes in research and development of drugs aimed at improving liver health, particularly in relation to non-alcoholic steatohepatitis (NASH) and cirrhosis. Madrigal Pharmaceuticals is known for its innovative technology targeting selective activation of liver receptors, which has the potential to provide effective therapeutic options for patients suffering from these complex and difficult-to-treat conditions.